Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion. - Kilic IB; Weberova P; VanDyke D; Sirova M; Kubesova K; Fabilane CS; Mazhara V; Liu K; Behalova K; Ptacek B; Rihova B; Spangler JB; et al. (Journal for immunotherapy of cancer, 2025)